| Literature DB >> 35053168 |
Mohammed Dalli1, Oussama Bekkouch1, Salah-Eddine Azizi1, Ali Azghar1, Nadia Gseyra1, Bonglee Kim2,3.
Abstract
Medicinal and aromatic plants are mainly characterized by the presence of different bioactive compounds which exhibit various therapeutic activities. In order to investigate the different pharmacological properties of different Nigella sativa extracts, a multitude of research articles published in the period between 2019 and 2021 were obtained from different databases (Scopus, Science Direct, PubMed, and Web of Science), and then explored and analyzed. The analysis of the collected articles allows us to classify the phytochemicals and the pharmacological activities through their underlying molecular mechanisms, as well as to explore the pharmacological activities exhibited by several identified compounds in Nigella sativa which allow a better understanding, and better elucidation, of the bioactive compounds responsible for the pharmacological effects. Also shown are the existence of other bioactive compounds that are still unexplored and could be of great interest. This review could be taken as a guide for future studies in the field.Entities:
Keywords: Nigella sativa; oil; organic extracts; pharmacological properties; thymoquinone
Mesh:
Substances:
Year: 2021 PMID: 35053168 PMCID: PMC8773974 DOI: 10.3390/biom12010020
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Some of the chemical compounds identified in the black cumin seeds using the GC-MS.
Figure 2Phenolic compounds present in Nigella sativa L.
Figure 3Nigella sativa isolated and identified alkaloids.
Figure 4Some saponins isolated from the aerial part of NS.
Figure 5Examples of fatty acids found in NS seeds.
Summary of the antioxidant activities of the NS.
| Extract/Compound | Methods | Test | Results | Reference |
|---|---|---|---|---|
|
| ||||
| In vitro | DPPH (antiradical scavenging activity) | IC50 = 1.367 mg TE/g | [ | |
| In vivo (Wistar rats) | Total antioxidant capacity (TAC) |
For 30 g/kg the TAC value was 1.0170 mmol/L For 50 g/kg the TAC value was 1.31 mmol/L | ||
| NSO | In vitro | DPPH | IC50 = 12.713 mM T/100 g | [ |
|
DPPH ABTS FRAP |
IC50 = 3.8 mg/mL IC50 = 4.7 mg/mL IC50 = 0.8 mg/mL | [ | ||
| In vivo | Wistar rats | ↓ MDA | ||
| MeOH extract | In vitro | Erythrocytes exposed to H2O2 | ↓ MDA | [ |
| EtOH extract | In vitro | Human umbilical vein endothelial cells H2O2 | ↑ GSH level | [ |
| In vivo | Wistar rats | ↓ DNA damages | ||
| TQ | In vitro | Irradiation HaCaT keratinocytes cells by the UVA | Inhibition of the cyclooxygenase 2 (COX2) via the activation of NrF2/ARE pathway. | [ |
| TQ | In vivo | Irradiation of Sprague Dawley rat kidney tissue | Arylesterase (not significant) | [ |
| Aqueous extract + honey | In vitro | DPPH | IC50 = 20 mg/mL | [ |
| Aqueous extract | In vivo | Human healthy subjects | ↓ MDA (not significant) | [ |
| MeOH extract | In vitro |
DPPH FRAP (ferric reducing power) |
Inhibition percentage reached 40.37% at 1000 µg/mL The percentage 48.4% at 100 µg/mL | [ |
| Water-soluble extract | In vitro | DPPH | IC50 = 33.32 mg/mL | [ |
|
Not roasted seeds Pan-roasted seeds Microwave roasted | In vitro | DPPH | Inhibition percentage of DPPH 87.76%, 86.14%, 87.11% respectively, for the different prepared seeds | [ |
| FRAP | The ferric reducing power percentage, 80.07%, 83.46%, 85.09% respectively for the different preparations | |||
|
| ||||
| Magnoflorine | In vitro |
DPPH ABTS |
IC50 = 71 µM IC50 = 139.2 µM | [ |
| Nigelflavonoside | In vitro |
DPPH ABTS |
IC50 = 32.7 µM IC50 = 95.18 µM | |
| Quercetin sphorotrioside | In vitro |
DPPH ABTS |
IC50 = 35.5 µM IC50 = 98.8 µM | |
| Kaempferol-3,7-diglucoside | In vitro |
DPPH ABTS |
IC50 = 197.8 µM IC50 = 247 µM | |
| Rutin | In vitro |
DPPH ABTS |
IC50 = 39.6µM IC50 = 129 µM | |
↑: Upregulation; ↓: Downregulation.
Figure 6Comprehensive summary of the NS pharmacological activities.
Summary of the antimicrobial activities of NS.
| Extract/Fraction | Method | Bacterial Strains | Results | Reference |
|---|---|---|---|---|
|
| ||||
| in vivo |
|
Eradication of Amelioration of body weight, and the body mass index. | [ | |
| MeOH fraction | in vitro |
S. aureus E. coli P. aeruginosa MRSA S. epidermis (MDR) | All tested bacteria showed a susceptibility toward the methanolic fraction | [ |
| in vitro | MRSA | Potentiation of the ATB activity, plus a membrane deformation | [ | |
| Aqueous extract | in vitro |
M. luteus S. aureus B. subtilis A. tumefaciens S. setubal E. aerogenes | MIC at 100 µg/mL | [ |
| Hexane extract | in vitro |
S.aureus (clinical strain) S.aureus (MTCC) S.typhi (MTCC) | Inhibitory activity on the tested strains that was characterized by an inhibition diameter between 11.25 to 19 mm. | [ |
| TQ | in vitro |
K.pneumoniae S.epidermis (ATCC) S.aureus S.epidermis Bacillus subtilis Bacillus licheniformis Chlamydia trachomatis |
Inhibitory activity of different gram+ and gram– bacteria with a MIC ranging from 1.04 to 8.3 µg/mL. Synergic activity in the presence of ATB Inhibition of bacterial growth Inhibition of bacterial growth IC50 = 3.12 µM | [ |
|
Fusobacterium nucleatum associated to Actinomyces naeslundii | Inhibition of biofilm formation at a concentration of 0.1% | |||
| NSO | in vitro |
Bacillus subtilis Bacillus licheniformis | A bacterial inhibition at a concentration of 5 µg/mL. | [ |
| in vivo | Injection of bacterial strains to A.hydrophila P.fluorescens | ↓ CYP1A | [ | |
| Aqueous extract | in vitro |
S.aureus E. coli | Inhibition diameter of about 13 mm. Inhibition diameter 6 mm. | [ |
| n-butanol extract | in vitro |
P. aeruginosa K. pneumoniae A.baumannii | A strong activity with an MIC value ranging from 0.25 to 1 µL/mL | [ |
|
E. coli S.aureus | Inactive | |||
| Essential oil | in vitro |
S. gallinarium S. enteriditis | Inactive | [ |
| in vitro |
| IC50 = 0.009% | ||
| in vitro |
| ↓ Total number of bacteria and also of the cold-resistant bacteria | [ | |
| in vitro |
MRSA Extended-spectrum
| An inhibitory potential with an MIC ranging from 3 to 20 µL/mL and an MBC value varies between (3 to 40 µL/mL). | [ | |
| Carvacrol | in vitro |
| IC50 = 6.25 µM | [ |
| Thymol | in vitro |
| IC50 = 6.25 µM | |
| in vitro | Inhibition of biofilm formation at a concentration of 0.1% | |||
| Cymene | in vitro |
| IC50 = 3.12 µM | |
|
| ||||
|
| ||||
| MeOH extract | in vitro |
Trichophyton sp. Candida albicans Candida tropicalis Candida krusei Penicillium sp. Aspergillus niger |
Inhibition of 66.67% of the tested fungi, while the 33.3% left were resistant. | [ |
| EtOH extract | in vitro |
Candida albicans - Candida parapsilosis |
MIC = 25 mg/mL MIC = 12.5 mg/mL | [ |
| n-butanol extract | in vitro |
Candida albicans Candida krusei Candida parapsilosi | MIC value between 0.125 and 0.5 µL/mL | [ |
| Sodium carboxymethylcellulose | in vivo | Injection of | Significant decrease of colonies at a dose of 6.6 mL/kg | [ |
| Hexane, Ethyl acetate, MeOH, Chloroform extracts (Obtained by methanolic extract fractionation) | in vitro |
Trichophyton sp. Candida albicans Candida tropicalis Candida krusei Penicillium sp. Aspergillus niger |
Hexane fraction was active on the different strains (2.0 to 50.0 mm) Chloroform fraction was active on only 33%. Ethyl acetate fraction had a zone inhibition ranging from (2.0 to 12.0 mm). The different tested strains were found to be sensitive to MeOH fractions except for | [ |
| Nigellothionines |
A. flavus A.fumigatus A.oryzae | The zone inhibition ranged from 11 to 12.7 mm, and the MIC was 0.77 µM | [ | |
|
| ||||
Ethyl acetate fraction n-hexane fraction n-butanol fraction Aqueous fraction | Antifungal bioassay |
Fusarium oxysporum Macrophomina phaseolina | The different fractions exhibited a biomass reduction at 50 mg/mL, except for the aqueous fraction that had a low activity | [ |
↑: Upregulation; ↓: Downregulation.
Summary of the anticancer activities of NS.
| Extract/Compound | Method | Cell Lines | Results | Reference |
|---|---|---|---|---|
| Aqueous extract | In vitro | Brine shrimp assay on artemia salina | Cytotoxic effect with an IC50 value equal to 284.9 mg/mL | [ |
| In vitro | Ovarian cancer cells PA-1 | Inhibition of the cell proliferation in a dose-dependent manner. | [ | |
| Aqueous extract prepared with mimicking the chewing process | In vitro | Mouse squamous cell carcinoma cells SCC VII | 5% of the diluted extract induced inhibition of cancer cell growth. | [ |
| α-hederin | In vitro | Mouse squamous cell carcinoma cells SCC VII | The α-hederin alone at a dose of 20 µg/mL induced an antiproliferative effect. | |
| Nigellothionines | In vitro |
B16 cells (Mice melanoma) HTC-116 (Human adenocarcinoma) Human postnatal fibroblasts (HPF) |
↓ Cell viability of the three used cell lines. The IC50 values registered were 0.30 for B16, 0.20 for HTC-116, and 0.55 for HPF. | [ |
| In vitro | THP-1 cells a human monocytic cell line |
↓ THP-1 cell viability to 90% as well as a cell arrest at the level of G0/G1 at 500 µg/mL. ↑ TLR4 | [ | |
|
HEK293 embryonic kidney cells |
Reduction of 80% of HEK293 cells at500 µg/mL. Blockage of the cell cycle at the G2 phase. No TLR 4 increase. | |||
|
Colorectal adenocarcinoma HT29 Colorectal cancer metastasis SW620 |
↑ ROS Activation of the JNK pathway. Inhibition of the ERK phosphorylation | |||
| NSO | In vivo | Balb/c mice | ↓ Polychromatic erythrocyte (PCE) at 500 mg/kg of NSO, and NSO + Cisplatin which indicated a bone marrow recovery. | [ |
| TQ | In vitro |
Liver cancer cells SK-Hep 1 Breast cancer cells MDA-MB 231 |
Activation of cell apoptosis ↑ P38 phosphorylation ↑ Extracellular signal-regulated kinases (ERK). Inhibition of cell proliferation at low doses of 50 and 100 µM | [ |
| Renal human cancer cells CaKi-1 |
↑ Pro-apoptotic markers P53, Bax, and Cytochrome C at 25 µM. ↓ Anti-apoptotic markers Bcl-2 and Bcl-xl. Inhibition of JAK2/STAT3 pathway phosphorylation which induces cyclin D1, cyclin D2, and the survivine inhibition. ↑ ROS | |||
| Ferulic acid | In vitro | Breast cancer cells MDA-MB 231 |
No effect was observed at 250 µM. Antiproliferative action at a dose of 450 µM. | |
| TQ + ferulic acid | 25 µM + 250 µM antiproliferative effect | |||
| Sapindoside B | In vitro | HCT116, AGS, and on HCC-LM3 | IC50 that was lower than 10 µM | [ |
| A549, H1299, H460, HGC27, and HepG2 | IC50 ranging from 11.93 to 20.05 µM | |||
| Gastric cancer cells MGC830 | Inactive | |||
| In vitro |
MCF5 A324 | LC50 1.6 µg/mL and 1.3 µg/mL for MCF5 and A325. | [ | |
| Virgin oil without volatile compounds | No effect even at high doses | |||
| Combination of ( | In vitro | Lung cancer cells NCI-H292 |
Cell morphology changes and reduction of the cell volume. 300 µg/mL induced DNA fragmentation. ↑ Caspase 3/7 activity at 50 µg/mL. Subexpression of Bac and P53 induced apoptosis of cancer cells. ↓ Heat shock proteins (Hsp) 70 and 90 | [ |
| Hydroalcoholic extract | In vitro | MCF-5 | IC50 value noted was 3.29 mg/mL | [ |
↑: Upregulation; ↓: Downregulation.
Summary of the anti-inflammatory and immunomodulatory activities of NS.
| Extract/Compound | Method | Test type | Results | Reference |
|---|---|---|---|---|
| NSO | In vivo | Inflammation caused by carrageenan on the rat’s path | Suppression of the edema | [ |
| Acute treatment and subacute |
Doses of 2 and 4 mL/kg showed their anti-inflammatory in the acute test. No activity in the subacute test. | |||
| In vivo | Injection of 10% PHA phytohemagglutinin to rats |
50 g/kg daily supplementation induced an increase in the size of the spleen ↑ IL-12. ↑ TNF-α ↑ IF-γ ↑ CD8 production. | [ | |
| Clinical study on patients with β-thalassemia | (2 g/d) for 3 months induced: ↑ Neutrophils, ↑ CD4, and ↑ CD8 ↑ Phagocytic capacity of macrophages | [ | ||
| Hydroalcoholic extract | In vivo |
|
↓ NFK and ↓ IKK mRNAs ↓ IL-1β ↓ CYP1A | [ |
| Ethanolic extract | In vivo | On lupus mice |
↓ anti-DNA Improvement of the Th1, and Th2 balance ↑ T-cells in lupus mice at 4.8 g/kg/d 200 mg/kg which may balance the Th1/Th2 cytokine profile | [ |
| In vivo | Injection cyclophosphamide CTX to mice | Protection of thymus and spleen against CTX-induced damage ↑ LDH ↑ Acid phosphatase ↑ TAC ↑ SOD ↑ CAT activity ↓ MDA. ↑ IL-2, IL-4, and IL-6 in the serum of mice. ↓ TNF-α, and regulation of cytokines level. | [ | |
| TQ | In vitro | Human monocytic leukemia cell line THP-1 |
Protection against subgingival inflammation Inhibition of TNF-α | [ |
↑: Upregulation; ↓: Downregulation.
Summary of the cardioprotective activities of NS.
| Extract/Compound | Method | Test | Results | Reference |
|---|---|---|---|---|
| NSO | In vivo | Clinical on patients suffering from hypertension (8 weeks treatment) | ↓ Systolic and Diastolic blood pressure | [ |
| In vivo | Pre-treatment of rats during 14 days by a dose of 4 mL/kg/day pursued with isoproterenol injection |
↓ Troponin, ↓ Creatinine kinase ↓ ASAT No effect on the complex QRS or the PR interval ↓ QT and QTc intervals No effect on R-wave amplitude. | [ | |
| In vivo | Cotreatment of rats using Azithromycin® and NSO |
↓ CPK ↓ LDH ↓ MDA ↓TNFα Preservation of cardiac morphology ↓ Caspase-3. | ||
| In vivo | Female rats with streptozotocin-induced diabetes |
Normal histological structure after treatment with NSO Hyperemia and hyaline degeneration in some muscle cells. ↑ Bcl-2 overexpression | ||
| In vivo | Clinical study on healthy obese and overweight subjects (2 g/day) |
↓ Systolic pressure No effect was observed on diastolic pressure | [ | |
| NS + amlodipine | In vivo | Hypertensive rats |
Better control of blood pressure ↓ Heart rate | [ |
| EtOH extract | Ex vivo | Aortic ring |
↓ Aortic contractions Improvement of the reactivity of the aorta to vasoconstrictor and vasodilator agents | [ |
| TQ | In vivo | Mice | ↓ Lipid deposition at the cardiac tissue | [ |
| In vivo | Rats |
Two months treatment induced an inotropic effect characterized by maximal tension that is mediated by increased sensitivity of contractile proteins to Ca2+ No effect on half-relaxation time and myocardial output |
↑: Upregulation; ↓: Downregulation.
Summary of the antidiabetic activities of NS.
| Extract/Fraction/Compound | Method | Test Type | Results | Reference |
|---|---|---|---|---|
|
| ||||
| In vivo | Glycated hemoglobin (5 g/day of black cumin for 6 months) | ↓ Glycated hemoglobin | [ | |
|
Volunteers Rats |
No effect on insulin secretion Regeneration of exocrine and endocrine parts of pancreatic tissues | [ | ||
| Hydroacetone extract | In vitro | α-amylase | IC50 = 314.4 µg/mL | [ |
| n-hexane fraction | In vitro | α -amylase | IC50 = 0.760 mg/mL | [ |
| EtOH fraction | IC50 = 0.255 mg/mL | |||
| MeOH fraction | IC50 = 0.103 mg/mL | |||
| Aqueous fraction | IC50 = 0.310 mg/mL | |||
| Dichloromethane fraction | IC50 = 1.330 mg/mL | |||
| Hydroalcoholic combination (70%) of | In vitro | α -amylase | 140/70/140 mg/kg was the most effective among the all doses with an IC50 = 35.7 µg/mL | [ |
| In vivo (rats) | ↓ blood glucose level in rats | |||
| n-hexane extract | In vitro |
α -amylase α -glucosidase Glycated hemoglobin |
IC50 = 403.5 µg/mL IC50 = 74.7 µg/mL ↓ Glycated hemoglobin | [ |
| Ethanolic extract | In vivo | Rats with streptozotocin-induced diabetes | 300 mg/kg of the ↓ Blood glucose (non-significant) ↓ Fructosamine Improvement in the number and morphology of islet cells | [ |
| In vitro | Glycation of bovine serum albumin | Antiglycation effect at different concentrations | ||
| MeOH extract | In vivo | Long–Evans rats |
↓ Blood glucose Suppression of sucrose-induced hyperglycemia ↑ unabsorbed sucrose Inhibition of disaccharidase enzyme | [ |
| Aqueous extract | In vitro | Glycation of bovine serum albumin | Antiglycation effect at different concentrations | [ |
| In vivo | Rats |
Protection of the pancreas’ proper functioning Ultrastructure study by transmission electron microscope (TEM) showed that the acinar cells had normal ultrastructure with normal cell activity and nuclei, and well-developed rough endoplasmic reticulum with abundant zymogen granules Protection against the degeneration caused by diabetes induced by alloxan injection | [ | |
| In vivo | Clinical study on overweight, type 2 diabetes, and overweight + type 2 diabetes |
↓ Glycated hemoglobin ↓ Liver enzymes | [ | |
| TQ (50 or 100 mg) with metformin (1000 mg) | In vivo | Clinical study on volunteers |
Adverse effects in some of the volunteers such as diarrhea and abdominal pain ↓ Glycated hemoglobin was observed after 3 months ↓ Fasting blood glucose ↓ Postprandial blood glucose | [ |
|
| ||||
| Hederagenin, |
In vitro |
α-glucosidase Phosphatase tyrosine kinase (PTP1B) |
IC50 ranging from 256.7 ±3.7 µM to 331.9 ± 1.6 µM No activity on PTP1B | [ |
| Flaccidoside III, | ||||
| Quercetin-3-gentiobiosides, | ||||
| Magnoflorin, | ||||
| Nigelflavonoside B, | ||||
| Nigelloside, | ||||
| Quercetin sphorotrioside, | ||||
| Kaempferol-3, | ||||
| Kaempferol 3-O- | ||||
| Rutin | ||||
| 3-O-[α-L-Rhamnopyranosyl-(1-2)-α-l-arabinopyranpsyl] hederagenin |
Phosphatase tyrosine kinase (PTP1B) | IC50 of 91.3 ± 2.5µM | ||
↑: Upregulation; ↓: Downregulation.
Summary of the hypolipidemic activities of NS.
| Extract/Compound | Method | Test Type | Results | Reference |
|---|---|---|---|---|
|
| ||||
| NSO | In vivo | Rats |
↓ Total cholesterol ↓ Low-density lipoproteins (LDL) ↓ Malondialdehyde (MDA) ↑ High-density lipoproteins (HDL) ↑ Glutathione reductase | [ |
| In vivo | Obese and overweight healthy women |
↑ HDL. ↓ Atherogenicity index ↓ LDL ↓ Serum glutamic-oxaloacetic transaminase | [ | |
| In vivo | overweight, type 2 diabetes, and overweight + type 2 diabetes volunteers |
↓ LDL ↓ TG ↓ VLDL ↓ Atherogenicity index. | [ | |
| TQ | In vivo | Mice |
↓ Total cholesterol ↓ LDL ↓ C-reactive proteins | [ |
| Hydroalcoholic extract | In vivo | Rats | Six weeks treatment ↓cholesterol ↓ TG ↓ LDL ↑ HDL | [ |
| In vivo | Volunteer patients with type 2 diabetes |
↓ Cholesterol ↓ LDL ↓ MDA ↓ Triglycerides ↑ HDL | [ | |
| In vivo | Rats |
↓ Cholesterol ↓ LDL ↓ Triglycerides ↓ ALAT and ASAT ↑ HDL | [ | |
↑: Upregulation; ↓: Downregulation.